These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21527299)

  • 21. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study.
    Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L
    Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04.
    Boland G; Beran J; Lievens M; Sasadeusz J; Dentico P; Nothdurft H; Zuckerman JN; Genton B; Steffen R; Loutan L; Van Hattum J; Stoffel M
    Vaccine; 2004 Dec; 23(3):316-20. PubMed ID: 15530674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.
    Langermans JA; Schmidt A; Vervenne RA; Birkett AJ; Calvo-Calle JM; Hensmann M; Thornton GB; Dubovsky F; Weiler H; Nardin E; Thomas AW
    Vaccine; 2005 Sep; 23(41):4935-43. PubMed ID: 15998554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
    Garçon N; Chomez P; Van Mechelen M
    Expert Rev Vaccines; 2007 Oct; 6(5):723-39. PubMed ID: 17931153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonclinical safety assessment of vaccines and adjuvants.
    Wolf JJ; Kaplanski CV; Lebron JA
    Methods Mol Biol; 2010; 626():29-40. PubMed ID: 20099119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
    Stoute JA; Gombe J; Withers MR; Siangla J; McKinney D; Onyango M; Cummings JF; Milman J; Tucker K; Soisson L; Stewart VA; Lyon JA; Angov E; Leach A; Cohen J; Kester KE; Ockenhouse CF; Holland CA; Diggs CL; Wittes J; Heppner DG;
    Vaccine; 2007 Jan; 25(1):176-84. PubMed ID: 16388879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.
    Pellegrini M; Nicolay U; Lindert K; Groth N; Della Cioppa G
    Vaccine; 2009 Nov; 27(49):6959-65. PubMed ID: 19751689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving vaccine delivery using novel adjuvant systems.
    Pichichero ME
    Hum Vaccin; 2008; 4(4):262-70. PubMed ID: 18398303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
    Baldridge JR; Crane RT
    Methods; 1999 Sep; 19(1):103-7. PubMed ID: 10525445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations.
    Miyaki C; Quintilio W; Miyaji EN; Botosso VF; Kubrusly FS; Santos FL; Iourtov D; Higashi HG; Raw I
    Vaccine; 2010 Mar; 28(13):2505-9. PubMed ID: 20123051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New adjuvants in evolving vaccine strategies.
    Buonaguro FM; Tornesello ML; Buonaguro L
    Expert Opin Biol Ther; 2011 Jul; 11(7):827-32. PubMed ID: 21609186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survey of human-use adjuvants.
    Kenney RT; Edelman R
    Expert Rev Vaccines; 2003 Apr; 2(2):167-88. PubMed ID: 12899569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
    Podda A; Del Giudice G
    Expert Rev Vaccines; 2003 Apr; 2(2):197-203. PubMed ID: 12899571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study.
    Esposito S; Birlutiu V; Jarcuska P; Perino A; Man SC; Vladareanu R; Meric D; Dobbelaere K; Thomas F; Descamps D
    Pediatr Infect Dis J; 2011 Mar; 30(3):e49-55. PubMed ID: 21273939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
    Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
    Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice.
    Mahboubi A; Fazeli MR; Dinarvand R; Samadi N; Sharifzadeh M; Ilka H; Azadi S; Soleimanian R; Kalkouei H; Hajikhanmirzaei R; Valadkhani M
    Iran J Immunol; 2008 Sep; 5(3):163-70. PubMed ID: 18791283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of the safety of aluminium adjuvant in the preparation of allergic rhinitis animal model].
    Fan EZ; Xi L; Han DM; Zhang SZ; Li Y; Zhang L
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Aug; 44(8):664-8. PubMed ID: 19961775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European union regulatory developments for new vaccine adjuvants and delivery systems.
    Sesardic D; Dobbelaer R
    Vaccine; 2004 Jun; 22(19):2452-6. PubMed ID: 15193409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.